NCI-H520 Xenograft Model Service for NSCLC

The NCI-H520 xenograft model offers a well-differentiated squamous cell carcinoma platform that captures the FGFR1-amplified, EGFR/KRAS-wild-type molecular landscape characteristic of a major NSCLC subtype. At Alfa Cytology, we deploy this authenticated squamous lineage model—complete with in-house histopathology, biomarker profiling, and flexible dosing architectures—to advance your preclinical pipeline from target validation through compound prioritization.

Overview of NCI-H520 Xenograft Model for NSCLC

The NCI-H520 cell line was established in 1982 by A.F. Gazdar and colleagues from a primary lung mass obtained from a male patient with squamous cell carcinoma. Unlike adenocarcinoma-derived NSCLC models, this line retains a wild-type ^EGFR and ^KRAS background, making it particularly valuable for evaluating therapeutic candidates outside the scope of canonical oncogene-driven pathways. The line harbors a truncating mutation in ^TP53 (Trp146Ter) that abolishes p53 function, coupled with focal amplification of the ^FGFR1 locus and gains in the ^CCND1 region—molecular hallmarks frequently observed in clinical lung squamous cell carcinoma. These alterations position NCI-H520 as a representative preclinical surrogate for investigating FGFR inhibitors, CDK4/6 modulators, and DNA-damage response agents in a histologically faithful context.

Fig 1. Phenotypic profiles of lung cells. (Ramos, Kenneth S., et al., 2020)

In immunodeficient hosts, NCI-H520 exhibits robust tumorigenicity with a 100% engraftment rate when 1×10⁷ cells are implanted subcutaneously, forming palpable masses within 7–10 days. Tumors progress to volumes of 800–900 mm³ over approximately five to six weeks, displaying consistent growth kinetics and reproducible squamous histology marked by keratin pearl formation, intercellular bridges, and dense eosinophilic cytoplasm. The model expresses cytokeratin 5/6, p63, and involucrin while remaining negative for neurofilament triplet protein, faithfully recapitulating the differentiated squamous phenotype and offering a reliable substrate for subtype-specific drug screening and resistance mechanism studies.

Cell Line Information: NCI-H520

The table below consolidates the essential biological, genetic, and culture parameters of the NCI-H520 cell line to guide experimental planning and data interpretation.

Our Services

Alfa Cytology offers a comprehensive NCI-H520 xenograft program built on authenticated cell stocks, stringent quality control, and adaptable study architectures. From initial cell banking and mycoplasma verification through tumor monitoring, dosing administration, and multi-modal endpoint analysis, our team ensures that every study generates consistent, audit-ready pharmacodynamic datasets tailored to squamous NSCLC drug development.

Workflow of NCI-H520 Xenograft Model Construction

Establishment of the NCI-H520 xenograft at Alfa Cytology proceeds through a standardized, IACUC-approved pipeline that emphasizes genetic fidelity, sterile technique, and reproducible tumor growth. Each stage is documented under GLP-aligned record-keeping to ensure complete traceability from cell vial to final report.

1. Cell Line Authentication & Expansion: NCI-H520 cells are revived from authenticated, low-passage master stocks and expanded in RPMI-1640 supplemented with 10% FBS. Each batch is screened for mycoplasma by PCR, confirmed by STR profiling, and verified to be in logarithmic growth phase before harvest.
2. Cell Harvest & Viability Assessment: Adherent cultures are dissociated with trypsin-EDTA, neutralized with complete medium, and pelleted by centrifugation at 125×g for 5–10 minutes. Cell viability is determined by trypan blue exclusion (target ≥95%), and the suspension is adjusted to 1×10⁸ cells/mL in ice-cold PBS for a final inoculum of 1×10⁷ cells per 100 μL.
3. Tumor Cell Inoculation: Six- to eight-week-old female athymic nude mice are acclimatized for seven days prior to surgery. Under aseptic conditions, 100 μL of the cell suspension is injected subcutaneously into the right flank using a 27-gauge needle. Matrigel may be co-injected at a 1:1 ratio to standardize engraftment kinetics when required by the study protocol.
4. Tumor Establishment & Randomization: Mice are monitored daily for general health. Once tumors become palpable (typically 7–10 days post-implantation) and reach a mean volume of 80–120 mm³, animals are randomized into vehicle control and treatment cohorts (n = 8–10 per group) using stratified randomization based on tumor size.
5. Dosing & Longitudinal Monitoring: Test compounds are administered according to the predefined schedule (PO, IP, IV, or SC) with dosing volumes and frequencies tailored to compound pharmacokinetics. Tumor dimensions and body weights are recorded twice weekly; tumor volume is calculated as (width)² × length / 2. Dosing continues for 21–28 days or until tumors approach the humane endpoint.
6. Endpoint Collection & Analysis: At study termination, mice are humanely euthanized and tumors are excised, weighed, and photographed. Tissues are allocated for histopathology (H&E), immunohistochemistry (CK5/6, p63, Ki-67, CD31, TUNEL), and molecular profiling (Western blot, qPCR, RNA-seq). Serum and plasma are banked for pharmacokinetic analysis where specified.

Fig 2. NCI-H520 xenograft model construction workflow.

Case Study

In a recent preclinical program, Alfa Cytology employed the NCI-H520 subcutaneous xenograft to assess the efficacy of a selective FGFR1 inhibitor in a squamous NSCLC context. Following robust tumor engraftment in female athymic nude mice, cohorts were randomized once mean tumor volume reached approximately 100 mm³ and dosed orally for 21 days at two escalating dose levels alongside a vehicle control arm. Tumor growth curves revealed a dose-dependent reduction in tumor burden relative to control, with the high-dose group exhibiting sustained growth suppression throughout the treatment interval. At necropsy, excised tumors were subjected to histopathological review and biomarker analysis, including CK5/6 and p63 staining to confirm squamous lineage retention, Ki-67 quantification to assess proliferative inhibition, and CD31 immunostaining to evaluate anti-angiogenic effects. Body weight trajectories remained stable across all groups, supporting an acceptable safety margin. Complete pharmacodynamic datasets, including individual tumor volume time courses and histology images, are available for disclosure under a confidentiality agreement.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your NCI-H520 xenograft partner provides access to a purpose-built infrastructure designed for squamous NSCLC preclinical research. Our operational framework integrates scientific rigor with client-centric flexibility to accelerate your compound decision timeline.

• Authenticated NCI-H520 master and working cell banks maintained under liquid nitrogen with quarterly STR confirmation and documented mycoplasma negativity ensure genetic consistency across studies.
• A 100% tumor take rate and well-characterized growth kinetics (800–900 mm³ at 5–6 weeks) enable precise power calculations and reduce the total animal numbers required for statistical significance.
• Customizable study arms support single-agent, combination, dose-escalation, and radiotherapy-addition designs, with dosing routes adapted to your compound formulation properties.
• On-site histopathology and IHC services—including CK5/6, p63, Ki-67, CD31, and TUNEL—deliver rapid turnaround without external vendor delays or sample custody gaps.
• Secure client data portals provide real-time access to tumor measurements, body weights, and study calendars, with automated alerts at protocol milestones.
• Each project is assigned a dedicated scientific liaison who coordinates weekly updates, interim data presentations, and protocol amendments to align with evolving program priorities.

Contact Us

If your research program targets the squamous NSCLC landscape—whether through FGFR1 inhibition, CDK4/6 modulation, or differentiation-directed strategies—Alfa Cytology provides the NCI-H520 xenograft expertise to advance your preclinical objectives with confidence. Contact us today to discuss your study parameters, request a tailored proposal, or arrange a consultation with our oncology model specialists. We are committed to translating your therapeutic hypothesis into rigorous, publication-ready preclinical data.

For research use only. Not intended for any clinical use.